Abstract Many local and systemic diseases especially diseases that are leading causes of death globally like chronic obstructive pulmonary disease, atherosclerosis with ischemic heart disease and stroke, cancer and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 19 (COVID-19), involve both, (1) oxidative stress with excessive production of reactive oxygen species (ROS) that lower glutathione (GSH) levels, and (2) inflammation
GR can perform its enzymatic activity in the cytoplasm, but also in the ER and within lysosomes, mitochondria and the nucleus
Skin and radiance focused protocols often pair glutathione with other nutrients, resulting in higher overall costs than a standalone infusion
A list of primers and plasmids are provided as separate Supplementary Data 1
Transient breathing discomfort or mild bronchospasm reported in some individuals, particularly those with asthma or sensitive airways
Excretion Pathways Excretion mechanisms for both peptides remain incompletely characterized: Renal filtration likely represents primary elimination route for peptide fragments Hepatic metabolism may contribute to peptide degradation and clearance No evidence of significant biliary excretion in available studies Pharmacokinetic studies in renal or hepatic impairment models are absent from literature The rapid systemic clearance of both peptides contrasts with prolonged downstream effects on growth hormone and IGF-1, indicating that direct peptide presence is not required for sustained biological activity once pituitary signaling cascades are initiated
